Abstract
In patients with diabetes, hyperglycemia is known to promote high levels of diacylglycerol which activates protein kinase C (PKC) in the vascular tissues and leads to the production of vascular endothelial growth factor (VEGF) in the retina. PKC activation and increased concentration of VEGF are likely to play a key role in diabetic microvascular complications, particularly change in vascular permeability, inflammation, fluid leakage and ischemia in the retina. PKC comprises a super family of isoenzymes that is activated in response to various stimuli. The PKC family consists of 12 isomers that possess distinct differences in structure, substrate requirement, expression and localization. PKC isomer selective inhibitors and VEGF trap are likely to be new therapeutics, which can delay the onset or stop the progression of diabetic vascular disease. A new promising therapy for diabetic retinopathy is undergoing Phase III trials, in which they proposed to target PKC βII isomer using Ruboxistaurin by oral administration. Besides retina, PKC βII isomer is found in higher concentration in brain, spleen, etc. So, oral targeting may be a questionable approach since generalized inhibitors may prove toxic in the treatment of diabetic retinopathy and ocular delivery may be a better alternative approach.
Keywords: Diabetic Retinopathy, PKC, VEGF, inhibitors, novel drug delivery approach
Current Drug Delivery
Title:Oral Targeting of Protein Kinase C Receptor: Promising Route for Diabetic Retinopathy?
Volume: 9 Issue: 4
Author(s): Deepa Pathak, Ankur Gupta, Bhagyashree Kamble, Gowthamarajan Kuppusamy and Bhojraj Suresh
Affiliation:
Keywords: Diabetic Retinopathy, PKC, VEGF, inhibitors, novel drug delivery approach
Abstract: In patients with diabetes, hyperglycemia is known to promote high levels of diacylglycerol which activates protein kinase C (PKC) in the vascular tissues and leads to the production of vascular endothelial growth factor (VEGF) in the retina. PKC activation and increased concentration of VEGF are likely to play a key role in diabetic microvascular complications, particularly change in vascular permeability, inflammation, fluid leakage and ischemia in the retina. PKC comprises a super family of isoenzymes that is activated in response to various stimuli. The PKC family consists of 12 isomers that possess distinct differences in structure, substrate requirement, expression and localization. PKC isomer selective inhibitors and VEGF trap are likely to be new therapeutics, which can delay the onset or stop the progression of diabetic vascular disease. A new promising therapy for diabetic retinopathy is undergoing Phase III trials, in which they proposed to target PKC βII isomer using Ruboxistaurin by oral administration. Besides retina, PKC βII isomer is found in higher concentration in brain, spleen, etc. So, oral targeting may be a questionable approach since generalized inhibitors may prove toxic in the treatment of diabetic retinopathy and ocular delivery may be a better alternative approach.
Export Options
About this article
Cite this article as:
Pathak Deepa, Gupta Ankur, Kamble Bhagyashree, Kuppusamy Gowthamarajan and Suresh Bhojraj, Oral Targeting of Protein Kinase C Receptor: Promising Route for Diabetic Retinopathy?, Current Drug Delivery 2012; 9 (4) . https://dx.doi.org/10.2174/156720112801323080
DOI https://dx.doi.org/10.2174/156720112801323080 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Future Targets in Endothelial Biology: Endothelial Cell to Mesenchymal Transition
Current Drug Targets Role of Statins in Peri-Operative Medicine
Current Drug Targets Effects of Vitamin C and E Against Oxidative Stress: Is Antioxidant Supplementation Efficient?
Current Nutraceuticals Interactions Between the Sympathetic Nervous System and Angiotensin System in Renovascular Hypertension
Current Hypertension Reviews Editorial [Hot Topic: Contrast Media: Induction of Side Effects and Pharmacological Treatment (Guest Editors: Ingrid Bohm & Hans H. Schild)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Inflammatory Cytokines and Cardiovascular Disease
Current Drug Targets - Inflammation & Allergy Nongenomic Actions of Retinoids: Role of Nur77 and RXR in the Regulation of Apoptosis and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Porphyromonas Gingivalis Antigenic Determinants - Potential Targets for the Vaccine Development against Periodontitis
Infectious Disorders - Drug Targets Patent Selections
Recent Patents on Cardiovascular Drug Discovery A Glance Over the Cannabinoid Machinery to Design New Anti- Angiogenic Compounds
Mini-Reviews in Medicinal Chemistry Ischemic and Oxidative Damage to the Hypothalamus May Be Responsible for Heat Stroke
Current Neuropharmacology Perivascular Adipose Tissue as an Endocrine Organ: The Role of Statins
Current Pharmaceutical Design microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease
Current Pharmaceutical Design Role of Vasa Vasorum in Arterial Disease: A Re-emerging Factor
Current Cardiology Reviews Recent Updates on Glucokinase Activators for the Treatment of Type 2 Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Is the Vascular System a Main Target for Thyroid Hormones? From Molecular and Biochemical Findings to Clinical Perspectives
Current Vascular Pharmacology Ca2+ Signalling in Damaged Endothelium and Arterial Remodelling: Do Connexin Hemichannels Provide a Suitable Target to Prevent In-stent Restenosis?
Current Drug Therapy Efficacy and Cardiovascular Safety of DPP-4 Inhibitors
Current Drug Safety Mechanisms of Medial Arterial Calcification in Diabetes
Current Pharmaceutical Design Understanding Membrane Protein Drug Targets in Computational Perspective
Current Drug Targets